@article{ref1,
title="Adjuvant and neo-adjuvant chemotherapy for Ewing's sarcoma family tumors and osteosarcoma of the extremity: further outcome for patients event-free survivors 5 years from the beginning of treatment",
journal="Annals of oncology",
year="2007",
author="Bacci, G. and Balladelli, A. and Forni, C. and Ferrari, S. and Longhi, A. and Benassi, M. S. and Briccoli, A. and Serra, M. and Picci, P.",
volume="18",
number="12",
pages="2037-2040",
abstract="BACKGROUND: In 326 patients with Ewing's sarcoma family tumor (ESFT) and 628 extremity osteosarcoma (OS) treated with adjuvant and neo-adjuvant chemotherapy and event-free survivors 5 years from the beginning of treatment we evaluated outcome in the following years. Post 5-year follow-up for these patients was 9.7 years (5.5-29 years). PATIENTS AND METHODS: Adverse events observed after 5-year follow-up were 73 (7.6%): 38 late relapses, nine leukemia, 14 second solid tumor, seven radioinduced sarcoma, three severe adriamycin-related cardiomyopathy, one suicide and one death by car crash. RESULTS: Of the patients who developed late events, 16 (22.5%) are alive and event free after 8 years from the last treatment (2-22 years). CONCLUSION: We conclude that the high rate of late adverse events after 5 years in patients with OS and ESFT is noteworthy and indicates that these patients should be followed for >5 years.<p /><p>Language: en</p>",
language="en",
issn="0923-7534",
doi="10.1093/annonc/mdm382",
url="http://dx.doi.org/10.1093/annonc/mdm382"
}